Komal Singh

Volunteer Faculty AR

500 North 3rd Street, Rm 284 Phoenix, AZ 85004
‌
‌

Long Bio

Komal Singh is an assistant professor with a joint appointment at Mayo Clinic. Her research interest focus is to improve cancer treatment-related outcomes. Singh evaluates phenotypic and molecular risk factors for symptom occurrence and severity to determine underlying mechanisms using omics based methodologies. Understanding the underlying biological mechanisms associated with patient symptom experience may yield targeted interventions to alleviate adverse events after chemotherapy. Currently, she's investigating associations between chemotherapy-induced nausea and disruption in the gut microbiome composition profiles.

Education

Post-doctoral fellow - University of California, San Francisco, CA

Ph.D. - University of California, San Francisco, CA

MS - Rutgers University-Piscataway, NJ

BSN/RN - Samuel Merritt University, CA

Curriculum Vitae

Research Interests

Investigate inter-individual differences in symptom experience
Evaluate phenotypic and molecular risk factors for symptom occurrence/severity and determine underlying mechanisms
Current focus for research – Chemotherapy-Induced Nausea (CIN)

Publications

1. Singh K, Dhruva A, Flowers E, Paul S, Hammer M, Wright F, Cartwright F, Conley Y, Melisko M, Levine J, Miaskowski C, Kober KM. Alterations in patterns of gene expression and perturbed pathways in the Gut-Brain Axis are associated with chemotherapy-induced nausea. Journal of Pain and Symptom Management. 2020;S0885-3924(19):31057-7. PubMed Central PMID: 31923555

2. Singh K, Paul S, Kober K, Conley Y, Wright F, Levine J, Joseph P, Miaskowski C. Neuropsychological symptoms and intrusive thoughts are associated with worse trajectories of chemotherapy-induced nausea. Journal of Pain and Symptom Management. 2019;S0885-3924(19):30640-2. PubMed Central PMID: 31689477

3. Singh K, Kober K, Paul S, Hammer M, Wright F, Conley Y, Levine J, Miaskowski C. Gastrointestinal symptoms are associated with trajectories of chemotherapy-induced nausea. Supportive Care in Cancer. 2019; doi:10.1007/s00520-019-05031-5. PubMed Central PMID: 31428931

4. Mazor M, Smoot B, Mastick J, Mausisa G, Paul S, Kober K, Elboim C, Singh K, Conley Y, Mickevicius G, Fileld J, Hutchison H, Miaskowski C. Assessment of local tissue water in the arms and trunk ofbreast cancer survivors with and without upper extremity lymphoedema. Clinical Physiology and Functional imaging. 2019;39(1):57-64. PubMed Central PMID: 30207039

5. Singh K, Kober K, Dhruva A, Flowers E, Paul S, Hammer M, Cartwright F, Wright F, Conley Y, Levine J, Miaskowski C. Risk factors associated with chemotherapy-induced nausea in the week prior to the next cycle and impact of nausea on quality of life outcomes. Journal of Pain and Symptom Management. 2018;56(3):352-362. PubMed Central PMID: 298857180

6. Singh K, Miaskowski C, Dhruva A, Flowers E, Kober K. Mechanisms and measurement of changes in gene expression. Biological Research for Nursing. 2018;20(4):369-382. PubMed Central PMID: 29706088.

7. Singh K, Dhruva A, Flowers E, Kober K, Miaskowskia C. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting. Critical Reviews in Oncology/Hematology. 2018;121:51-61. PubMed Central PMCID: PMC5777158, PMID: 29279099

8. Flowers E, Singh K, Molina C, Mathur A, Aouizerat B. MicroRNA associated with atherogenic dyslipidemia in South Asian men. International Journal of Cardiology. 2013;168(5):4884-4885. PubMed Central PMCID: PMC3809319, PMID: 23871617

9. Qian Z, Wang H, Singh K, Rao G, Ho M, Ryder T. High quality performance of high-throughput GeneChip Probe Array System. Conf Proc IEEE Eng Med Biol Soc. 2005;1:1032-1035. PubMed Central PMID: 17282363

10. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh K, Vega F, To W, Wagner J, O'Farrell A, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick D, Kastelein R, de Waal Malefyt R, Moore K. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. Journal of Immunology. 2002;168(11):5699-5708. PubMed Central PMID: 12023369

11. Oppmann B, Lesley R, Blom B, Timans J, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams J, Moore K, Rennick D, de Waal-Malefyt R, Hannum C, Bazan J, Kastelein R. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725. PubMed Central PMID: 11114383

12. Thieringer H, Singh K, Trivedi H, Inouye M. Identification and developmental characterization of a novel Y-box protein from Drosophila melanogaster. Nucleic Acids Research. 1997;25(23):4764-4770. PubMed Central PMCID: PMC147121, PMID: 9365254.

13. Vicari A, Figueroa D, Hedrick, Foster J, Singh K, Menon S, Copeland N, Gilbert D, Jenkins N, Bacon K, Zlotnik A. A novel chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity. 1997;7:291-301. PubMed Central PMID: 9285413

MANUSCRIPT ACCEPTED FOR PUBLICATION

12. Singh K, Miaskowski CM, Conley YP, Hammer M, Wright F, Levine J, Cao H, Kober KM. Perturbations in endocytotic and apoptotic pathways are associated with chemotherapy-induced nausea. Biological Research for Nursing. 2021. Accepted for publication

Research Activity

FUNDED RESEARCH (INTERNAL)

Tenure Track Assistant Professor at Arizona State University (ASU) and Principal Investigator. A Pilot Study of the Associations Between Chemotherapy-Induced Nausea in Breast Cancer Patients and Gut Microbiome Composition Profiles. Funded by Institute for Social Sciences Research (ISSR) from 05/15/20 - 05/15/20 Total ASU budget: $8000/year. This research project built on my post-doctoral and pre-doctoral work. This study will: evaluate feasibility of patient recruitment and retention, as well as specimen collection; and estimate the effect size for changes in gut microbiome composition profiles from T1 to T2 that are associated with the occurrence of CIN.

FUNDED RESEARCH (EXTERNAL)

Post-doctoral Fellow. Evaluate Phenotypic and Molecular Predictors of Chemotherapy-Induced Nausea. Funded by T32 NR016920 (NIH/NINR) Weiss/Miaskowski (multiple PIs) from 09/01/18-08/31/19. Total UCSF budget: Tuition + $51,000/year. My postdoctoral research project built on my pre-doctoral work. This study evaluated: additional molecular mechanisms associated with chemotherapy-induced nausea, and phenotypic risk factors associated with trajectories of chemotherapy-induced nausea over two cycles of chemotherapy. As a member of Dr. Miaskowski’s research team, I recruited and assessed breast cancer patients to investigate molecular and phenotypic risk factors associated with developing lymphedema after treatment.

Doctoral student. Evaluate Molecular Predictors of Chemotherapy-Induced Nausea. Funded by T32 NR016920 (NIH/NINR) Weiss/Miaskowski (multiple PIs) from 09/01/17-08/31/18. Total UCSF budget: Tuition + $24,000/year. This part of my doctoral research study evaluated the differentially expressed genes and perturbed biological pathways between patients who did and did not experience chemotherapy-induced nausea and determine molecular mechanisms associated with chemotherapy-induced nausea. In addition, as a member of Dr. Miaskowski’s research team, I recruited and assessed breast cancer patients to investigate molecular and phenotypic risk factors associated with developing lymphedema after treatment.

Doctoral student. Evaluate Molecular Predictors of Chemotherapy-Induced Nausea. Funded by T32 NR007088 (NIH/NINR) Weiss/Miaskowski (multiple PIs) from 04/01/15-05/31/16. Total UCSF budget: Tuition + $24,000/year. This initial step of my doctoral research study analyzed data for differentially expressed genes between patients who did and did not experience chemotherapy-induced nausea using gene expression methodologies (i.e., RNA-Sequencing and microarrays using patient blood samples) with a goal to determine molecular mechanisms associated with chemotherapy-induced nausea.

Doctoral student and Principal Investigator. Evaluate Phenotypic Risk Factors for Chemotherapy-Induced Nausea. Funded by American Cancer Society

(Grant number DSCN-15-095-01-SCN) from 09/01/15-08/31/17. Total UCSF budget: $30,000. This part of my doctoral research study evaluated for differences in demographic and clinical characteristics, symptom severity, perceived stress and QOL outcomes between patients who did and did not report chemotherapy-induced nausea in the week prior to their next dose of chemotherapy. In addition, demographic, clinical, symptom and stress characteristics were evaluated as risk factors for nausea group membership.

Doctoral student. Travel award. Funded by K-award (Grant number CA168960) Dr. Christine Miaskowski (PI) from 09/ 2014 – 05/2018. Total UCSF budget: $20,000. Funds were used for poster and podium presentation at national and international conferences.

Doctoral student and Principal Investigator. Evaluate Phenotypic Risk Factors for Chemotherapy-Induced Nausea. Funded by El Camino Hospital Auxiliary Doctoral Scholarship from 09/2015 – 09/2017. Total UCSF budget: $3,500. This funding supported my training in statistics for doctoral research.

Graduate Student and Principal Investigator. Characterize Function of Cold Shock Proteins in Drosophila. Funded by NIH Graduate Research Fellowship from 09/1993 – 09/1995. Total Rutgers University budget: Tuition + $24,000. This study evaluated novel proteins as drug targets to inhibit DNA replication in eukaryotic cells.

Teaching Website URL

https://canvas.asu.edu/courses/70618

Courses

2021 Spring

Course Number	Course Title
NUR 610	Genomics and Population Health

2020 Fall

Course Number	Course Title
DNP 679	BiostatPrincipleStatsInference

2020 Summer

Course Number	Course Title
NUR 444	Innovation in Nursing

2020 Spring

Course Number	Course Title
DNP 602	Evaluating Research Practice

Presentations

Spring 2021 - NUR 610 Genomics and Population Health

Industry Positions

2012-2014 Illumina Inc., San Francisco, CA Senior Research Associate, Next-Gen Human Genome Library Sequencing, Research and Development Group

2010-2012 Complete Genomics Inc. Senior Molecular Biologist, Mountain View, CA Human Genome Library Preparation and Sequencing Group

2001-2010 Affymetrix Inc., Santa Clara, CA Senior Research Associate, Gene Expression and Genotyping Product Development Group

1996-2001 Merck Research Institute, Palo Alto, CA Scientist, Receptor Ligand Assay Group

Expertise Areas